- Home
- VPG vs MRSN Comparison
VPG vs MRSN Comparison
Compare VPG & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VPG
- MRSN
- Stock Information
- Founded
- VPG 2009
- MRSN 2001
- Country
- VPG United States
- MRSN United States
- Employees
- VPG N/A
- MRSN N/A
- Industry
- VPG Electrical Products
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- VPG Technology
- MRSN Health Care
- Exchange
- VPG Nasdaq
- MRSN Nasdaq
- Market Cap
- VPG 283.7M
- MRSN 252.0M
- IPO Year
- VPG N/A
- MRSN 2017
- Fundamental
- Price
- VPG $24.38
- MRSN $1.86
- Analyst Decision
- VPG Hold
- MRSN Buy
- Analyst Count
- VPG 1
- MRSN 6
- Target Price
- VPG $31.00
- MRSN $6.00
- AVG Volume (30 Days)
- VPG 134.4K
- MRSN 1.1M
- Earning Date
- VPG 11-05-2024
- MRSN 11-13-2024
- Dividend Yield
- VPG N/A
- MRSN N/A
- EPS Growth
- VPG N/A
- MRSN N/A
- EPS
- VPG 0.99
- MRSN N/A
- Revenue
- VPG $323,397,000.00
- MRSN $34,837,000.00
- Revenue This Year
- VPG N/A
- MRSN N/A
- Revenue Next Year
- VPG $1.31
- MRSN N/A
- P/E Ratio
- VPG $24.45
- MRSN N/A
- Revenue Growth
- VPG N/A
- MRSN N/A
- 52 Week Low
- VPG $20.83
- MRSN $1.22
- 52 Week High
- VPG $35.98
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- VPG 56.18
- MRSN 42.16
- Support Level
- VPG $23.68
- MRSN $1.93
- Resistance Level
- VPG $25.44
- MRSN $2.81
- Average True Range (ATR)
- VPG 0.87
- MRSN 0.24
- MACD
- VPG 0.09
- MRSN -0.05
- Stochastic Oscillator
- VPG 57.55
- MRSN 7.79
About VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates majority of its revenue from United States.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.